The only currently available treatment for AATD apart from transplantation is augmentation therapy consisting of weekly or bi-weekly intravenous delivery of exogenous plasma derived AAT protein and has pulmonary loss of function as the primary indication12,23,24. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.